LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma
A Phase I, Multicenter study to evaluate the safety, tolerability, and Efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+T Lymphocyte Tumor Patients.
CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)
DRUG: Efficacy of LCAR-T2C CAR-T cells
Dose limiting toxicity (DLT), DLT assessed by NCI-CTCAE 5.0, 30 days post infusion|Adverse events, Incidence and severity of adverse events as assessed by NCI-CTCAE 5.0, 90 days post infusion|Recommended Phase II dose (RP2D), RP2D established through ATD+BOIN design and the DLTs occurring following CAR T-cell infusion, 30 days post infusion|Pharmacokinetics, PK CAR positive T cells in peripheral blood, PK CAR transgene levels in peripheral blood, PK CAR positive T cells in bone marrow and PK CAR transgene levels in bone marrow., through study completion, 2 years after infusion of the last subject
Anti-drug antibody, Anti-drug antibody (ADA) will be conducted on blood sample for immune response analyses., through study completion, 2 years after infusion of the last subject|Overall response rate (ORR) after administration, through study completion, 2 years after infusion of the last subject|Time to Response (TTR) after administration, through study completion, 2 years after infusion of the last subject|Duration of remission (DOR) after administration, through study completion, 2 years after infusion of the last subject|Progress Free Survival (PFS) after administration, through study completion, 2 years after infusion of the last subject|Over Survival (OS) after administration, through study completion, 2 years after infusion of the last subject
This is an open, dose escalation/dose extension study of LCAR-T2C CAR-T cells administrered to patients with T lymphocyte tumor. The aim of the study is to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells. The auto-CAR-T cells will be infused in single-dose.